The utility of anti-trypomastigote lytic antibodies for determining cure of Trypanosoma cruzi infections in treated patients: An overview and perspectives

Memorias do Instituto Oswaldo Cruz

Volumn 104, Issue SUPPL. 1, 2009, Pages 142-151

  Krettli, Antoniana Ursine ^a  

^a INSTITUTO OSWALDO CRUZ   (Brazil)

Author keywords

Cure; Drug treatment; Lytic antibodies; Trypanosoma cruzi; Trypomastigotes

Indexed keywords

TRYPANOSOMA CRUZI;

EID: 68949210754     PISSN: 00740276     EISSN: 16788060     Source Type: Journal    
DOI: 10.1590/S0074-02762009000900020     Document Type: Article

References (49)

1. Almeida IC, Krautz GM, Krettli AU, Travassos LR 1993. Glycoconjugates of Trypanosoma cruzi: a 74 kD antigen of trypomastigotes specifically reacts with lytic anti-α-galactosyl antibodies from patients with chronic Chagas disease. J Clin Lab Anal 7: 307-316.
2. Andrade HM, Murta SM, Chapeaurouge A, Perales J, Nirdé P, Romanha AJ 2008. Proteomic analysis of Trypanosoma cruzi resistance to Benznidazole. J Proteome Res. 7: 2357-2367.
3. Caballero ZC, Sousa OE, Marques WP, Saez-Alquezar A, Umezawa ES 2007. Evaluation of serological tests to identify Trypanosoma cruzi infection in humans and determine cross-reactivity with Trypanosoma rangeli and Leishmania spp. Clin Vaccine Immunol 14: 1045-1049.
4. Camargo EP 1964. Growth and differentiation in Trypanosoma cruzi. I. Origin of metacyclic trypanosome in liquid media. Rev Inst Med Trop São Paulo 6: 93-100.
5. Camargo ME, Segura EL, Kagan IG, Pacheco-Souza JM, Carvalheiro JR, Yanovsky JF, Guimaraes MCS 1986. Three years of collaboration on the standardization of Chagas disease serodiagnosis in the Americas: an appraisal. Bull Pan Am Health Organ 20: 233-244.
6. Chagas CRJ 1909. Nova tripanozomiaze humana: estudos sobre a morfolojia e o ciclo evolutivo do Schizotrypanum cruzi n. gen., n. sp., ajente etiolojico de nova entidade morbida do homem. Mem Inst Oswaldo Cruz 1: 159-218.
7. Coura JR 2007. Chagas disease: what is known and what is needed. A background article. Mem Inst Oswaldo Cruz 102 (Suppl. I): 113-122.
8. Dias JC 2007. Southern Cone Initiative for the elimination of domestic populations of Triatoma infestans and the interruption of transfusional Chagas disease. Historical aspects, present situation and perspectives. Mem Inst Oswaldo Cruz 102 (Suppl. I): 11-18.
9. Filardi LS, Brener Z 1987. Susceptibility and natural resistance of Trypanosoma cruzi strains to drugs used clinically in Chaga's disease. Trans R Soc Trop Med Hyg 81: 755-759.
10. Gadelha AA, Verçosa AF, Lorena VM, Nakazawa M, Carvalho AB, Souza WV, Ferreira AG, Silva ED, Krieger MA, Goldenberg S, Gomes YM 2003. Chagas' disease diagnosis: comparative analysis of recombinant ELISA with conventional ELISA and the haemagglutination test. Vox Sang 85: 165-170.
11. Galvão LMC, Nunes RMB, Cançado JR, Brener Z, Krettli AU 1993. Lytic antibody titre as a means of assessing cure after treatment of Chagas disease: a 10 years follow-up study. Trans R Soc Trop Med Hyg 87: 220-223.
12. Garcia S, Ramos CO, Senra JFV, Vilas-Boas F, Rodrigues MM, Campos-de-Carvalho AC, Santos RR, Soares MPB 2005. Treatment with Benznidazole during the chronic phase of experimental Chagas' disease decreases cardiac alterations in mice. Antimicrob Agents Chemother 49: 1521-1528.
13. Gazzinelli RT, Galvão LMC, Cardoso JE, Cançado JR, Krettli AU, Brener Z, Gazzinelli G 1988. Anti-Trypanosoma cruzi and anti-laminin antibodies in chagasic patients after specific treatment. J Clin Microbiol 26: 1795-1800.
14. Gazzinelli RT, Galvão LMC, Krautz G, Lima APCA, Cançado JR, Scharfstein J, Krettli AU 1993. Use of Trypanosoma cruzi purified glycoprotein (GP57/51) or trypomastigote-shed antigens to assess cure for human Chagas' disease. Am J Trop Med Hyg 49: 625-635.
15. Gazzinelli RT, Morato MJF, Galvão LMC, Krettli AU, Cançado JR, Brener Z, Gazzinelli G 1987. An immunological study of treated and untreated Chagas disease patients. Bras Arch Biol Technol 30: 182.
16. Guerreiro C, Machado A 1913. Da reação de Bordet e Gengou na moléstia de Carlos Chagas como elemento de diagnóstico. Bras Med 23: 225-226.
17. Israelski DM, Sadler R, Araujo FG 1985. Antibody response and antigen recognition in human infection with Trypanosoma cruzi Am J Trap Med Hyg 39: 445-455.
18. Kipnis TL, Krettli AU, Dias da Silva W 1985. Transformation of trypomastigote forms of Trypanosoma cruzi into activators of alternative complement pathway by immune IgG fragments. Scand J Immunol 22: 217-226.
19. Krautz GM, Coutinho MG, Galvão LMC, Cançado JR, Krettli AU 1994. Antígenos solúveis liberados por tripomastigotas de Trypanosoma cruzi utilizados no teste de ELISA para detectar cura em pacientes chagásicos após tratamento específico. Rev Soc Bras Med Trop 27: 199-207.
20. Krautz GM, Galvão LMC, Cançado JR, Guevara-Espinoza A, Ouaissi A, Krettli AU 1995. Use of a 24-kilodalton Trypanosoma cruzi recombinant protein to monitor cure of human Chagas' disease. J Clin Microbiol 33: 2086-2090.
21. Krautz GM, Kissinger JC, Krettli AU 2000. The targets of the lytic antibody response against Trypanosoma cruzi. Parasitol Today 16: 31-34.
22. Krautz GM, Peterson JD, Godsel LM, Krettli AU, Engman D 1998. Human antibody responses to Trypanosoma cruzi 70-kDa heatshock proteins. Am J Trop Med Hyg 58: 137-143.
23. Krettli AU 1978. Efeito de anticorpos e do complemento sobre tripomastigotas sanguineos de camundongos infectados com Try- panosoma cruzi, PhD Thesis, Universidade Federal de Minas Gerais, Belo Horizonte, 111 pp.
24. Krettli AU, Brener Z 1976. Protective effects of specific antibodies in Trypanosoma cruzi infections. J Immunol 116: 755-760.
25. Krettli AU, Brener Z 1982. Resistance against Trypanosoma cruzi associated to anti-living trypomastigote antibodies. J Immunol 128: 2009-2012.
26. Krettli AU, Cançado JR, Brener Z 1982. Effect of specific chemotherapy on the levels of lytic antibodies in Chagas's disease. Trans R Soc Trop Med Hyg 76: 334-340.
27. Krettli AU, Weisz-Carrington P, Nussenzweig RS 1979. Membrane-bound antibodies to bloodstream Trypanosoma cruzi in mice: strain differences in susceptibility to complement-mediated lysis. Clin Exp Immunol 37: 416-423.
28. Krieger MA, Almeida E, Oelemann W, Lafaille JJ, Pereira JB, Krieger H, Carvalho MR, Goldenberg S 1992. Use of recombinant antigens for the accurate immunodiagnosis of Chagas' disease. Am J Trop Med Hyg 46: 427-434.
29. Leiby DA, Wendel S, Takaoka DT, Fachini RM, Oliveira LC, Tibbals MA 2000. Serologic testing for Trypanosoma cruzi: comparison of radioimmunoprecipitation assay with commercially available indirect immunofluorescence assay, indirect hemagglutination assay and enzyme-linked immunosorbent assay kits. J Clin Microbiol 38: 639-642.
30. Lorena VM, Verçosa AF, Machado RC, Moitinho-Silva L, Cavalcanti MG, Silva ED, Ferreira AG, Correa-Oliveira R, Pereira VR, Gomes YM 2008. Cellular immune response from chagasic patients to CRA or FRA recombinant antigens of Trypanosoma cruzi. J Clin Lab Anal 22: 91-98.
31. Martins MS, Hudson L, Krettli AU, Cançado JR, Brener Z 1985. Human and mouse sera recognize the same polypeptide associated with immunological resistance to Trypanosoma cruzi infection. Clin Exp Immunol 61: 343-350.
32. Martins-Filho OA, Eloi-Santos SM, Carvalho AT, Oliveira RC, Rassi A, Luquetti AO, Rassi GG, Brener Z 2002. Double-blind study to evaluate flow cytometry analysis of anti-live trypomastigote antibodies for monitoring treatment efficacy in cases of human Chagas' disease. Clin Diagn Lab Immunol 9: 1107-1113.
33. Martins-Filho OA, Pereira MES, Carvalho JF, Cancado Jr, Brener Z 1995. Flow-cytometry, a new approach to detect anti-live trypomastigote antibodies and monitor the efficacy of specific treatment in human Chagas disease. Clin Diagn Lab Immunol 2: 569-573.
34. Meira WSF, Galvao LMC, Gontijo ED, Machado-Coelho GLL, Norris KA, Chiari E 2004. Use of the Trypanosoma cruzi recombinant complement regulatory protein to evaluate therapeutic efficacy following treatment of chronic chagasic patients. J Clin Microbiol 42: 707-712.
35. Moncayo A, MI Ortiz Yanine 2006. An update on Chagas disease (human American trypanosomiasis). Ann Trop Med Parasitol 100: 663-677.
36. Muniz J, Freitas G 1944a. Contribuição para o diagnóstico da doença de Chagas pelas reações de imunidade. I - Estudo comparativo entre as reações de aglutinação e de fixação de complemento. Mem Inst Oswaldo Cruz 41: 303-333.
37. Muniz J, Freitas G 1944b. Contribuição para o diagnóstico da doença de Chagas pelas reações de imunidade. II - Isolamento de polisacarídeos de Schizotrypanum cruzi e de outros tripanosomídeos, seu comportamento nas reações de precipitação, de fixação do complemento e de hipersensibilidade. Os "tests" de floculação (sublimado e formol-gel). Rev Bras Biol 4: 421-438.
38. Norris KA, Bradt B, Cooper NR, So M 1991. Characterization of a Trypanosoma cruzi C3 binding-protein with functional and genetic similarities to the human-complement regulatory protein, decay-accelerating factor. J Immunol 147: 2240-2247.
39. Norris KA, Galvão LMC, Schrimpf JE, Cançado JR, Krettli AU 1994. Humoral immune response to the Trypanosoma cruzi complement regulatory protein as an indicator of parasitologic clearance in human Chagas' disease. Infect Immu 62: 4072-4074.
40. Passos VMA, Volpini AC, Braga EM, Lacerda PAF, Ouaissi A, Lima-Martins MVC, Krettli AU 1997. Differential serodiagnosis of human infections caused by Trypanosoma cruzi and Leishmania spp. using ELISA with a recombinant antigen (rTc24). Mem Inst Oswaldo Cruz 92: 791-793.
41. Rassi-Jr A, Rassi A, Little WC, Sérgio SX, Xavier SR, Rassi AG, Rassi GG, Hasslocher-Moreno, Sousa AS, Scanavacca MI 2006. Development and validation of a risk score for predicting death in Chagas' heart disease. N Engl J Med 355: 799-808.
42. Sartori AM, Lopes MH, Benvenuti LA, Caramelli B, di Pietro A, Nunes EV, Ramirez LP, Shikanai-Yasuda MA 1998. Reactivation of Chagas' disease in a human immunodeficiency virus-infected patient leading to severe heart disease with a late positive direct microscopic examination of the blood. Am J Trop Med Hyg 59: 784-786.
43. Scharfstein J, Rodrigues MM, Alves CA, De Souza W, Previato JO, Mendonca-Previato L 1983. Trypanosoma cruzi: description of highly purified surface antigen defined by human antibodies. J Immunol 131: 972-976.
44. Shikanai-Yasuda MA, Marcondes CB, Guedes LA, Siqueira GS, Barone AA, Dias JC, Amato Neto V, Tolezano JE, Peres BA, Arruda Júnior ER, Lopes MH, Shiroma M, Chapadeiro E 1991. Possible oral transmission of acute Chagas' disease in Brazil. Rev Inst Med Trop São Paulo 33: 351-357.
45. Silva ED, Pereira VR, Gomes JA, Lorena VM, Cançado JR, Ferreira AG, Krieger MA, Goldenberg S, Correa-Oliveira R, Gomes YM 2002. Use of the EIE-recombinant-Chagas-Biomanguinhos kit to monitor cure of human Chagas' disease. J Clin Lab Anal 16: 132-136.
46. Silva LHP, Nussenzweig V 1953. Sobre uma cepa de Trypanosoma cruzi altamente virulenta para o camundongo branco. Folia Clin Biol (São Paulo) 20: 191-208.
47. Snary D, Hudson L 1979. Trypanosoma cruzi cell surface proteins: identification of a major glycoprotein. FEBS Lett 100: 166.
48. Umezawa ES, Bastos SF, Coura JR, Levin MJ, Gonzalez A, Rangel-Aldao R, Zingales B, Luquetti AO, da Silveira JF 2003. An improved serodiagnostic test for Chagas' disease employing a mixture of Trypanosoma cruzi recombinant antigens. Transfusion 43: 91-97.
49. Viotti R, Vigliano C, Lococo B, Alvarez MG, Petti M, Bertocchi G, Armenti A 2009. Side effects of Benznidazole as treatment in chronic Chagas disease: fears and realities. Expert Rev Anti Infect Ther 7: 157-163.